Primary safety and effectiveness feasibility study after surgical aortic valve replacement with a new generation bioprosthesis: one-year outcomes

Abstract

The new generation RESILIA™ tissue aortic valve bioprosthesis demonstrated excellent haemodynamic per-formance and safety outcomes at one year of follow-up. Longer follow-up of these patients will provide further insight on long-term durability.

Trends in isolated aortic valve replacement in middle‑aged patients over the last 10 years: epidemiology, risk factors, valve pathology, valve types, and outcomes

“…Both valve prosthesis types, mechanical valves (MV) and biological valves (BV), have disadvantages and advantages. 1,2,[4][5][6][7] In borderline patients, many factors are considered, including prosthesis parameters and patient preferences. Therefore, in middle -aged patients, the selection of valve prosthesis type is difficult and requires complex decision making.…”

“…Therefore, in middle -aged patients, the selection of valve prosthesis type is difficult and requires complex decision making. 7 In this study, we presented real-time -related trends in isolated aortic valve replacement in patients between 60 and 70 years of age based on a large cohort of 1531 cases. Ten -year trends were assessed by comparing patient characteristics, risk factor distribution, aortic valve pathology, valve types, surgical outcomes, and in--hospital mortality.…”

“…5,19 Additionally, the durability of new generation BVs with good hemodynamic parameters is comparable with that of MVs. 7,18 Furthermore, a valve -in -valve procedure using TAVI may be used in high -risk patients undergoing reoperation after an initial BV implantation. 20 In our study, the mean age in the MV group was slightly lower than that reported in other studies.…”

“…14,15 In contrast, BVs do not require oral anticoagulation and are associated with lower risk of major bleeding. 6,7,14,15 However, they are less durable, which limits their use, particularly in younger patients. 6,7,14,15 The current American and European guidelines specify that patient age affects the recommendations.…”

“…6,7,14,15 However, they are less durable, which limits their use, particularly in younger patients. 6,7,14,15 The current American and European guidelines specify that patient age affects the recommendations. In patients under 60 years of age, with no contraindications to warfarin therapy, MV is recommended (ESC/EACTS and AHA/ACC guidelines, class IIa recommendation).…”